Streetbeat News

Stock Prices

PBYI

Puma Biotechnology (NASDAQ:PBYI) has received consistent 'Buy' ratings from analysts at HC Wainwright & Co. over the past three months, with a stable 12-month price target of $7.00. Despite facing revenue challenges and a high debt-to-equity ratio, the company shows strong net margin, ROE, and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

July 26, 2024 | 9:01 pm

LII

Over the past three months, 10 analysts have shared their evaluations of Lennox Intl (NYSE:LII), revealing diverse outlooks. The average 12-month price target has increased to $581.9, reflecting a 7.66% rise from the previous target. Analysts have predominantly raised their price targets, indicating a positive sentiment towards the stock.

Portfolio Pulse from Benzinga Insights

July 26, 2024 | 9:01 pm

TSM

Taiwan Semiconductor (NYSE:TSM) has significantly outperformed the market over the past decade, delivering an average annual return of 23.26%. A $1000 investment in TSM 10 years ago would be worth $7,815.64 today. The company's current market capitalization is $837.03 billion.

Portfolio Pulse from Benzinga Insights

July 26, 2024 | 9:01 pm

CNQ

Canadian Natural Res (NYSE:CNQ) has outperformed the market over the past 5 years with an average annual return of 22.36%, significantly higher than the market average. A $100 investment in CNQ 5 years ago would now be worth $279.38.

Portfolio Pulse from Benzinga Insights

July 26, 2024 | 9:00 pm

FCAP

First Cap (NASDAQ:FCAP) reported a 3.66% increase in Q2 earnings per share (EPS), rising from $0.82 to $0.85 year-over-year.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 8:46 pm

KSS

Kohl's (NYSE:KSS) has seen a 4.82% increase in its short percent of float, now at 51.14%. This indicates a bearish sentiment among investors. It would take traders 8.49 days to cover their short positions. Kohl's short interest is significantly higher than its peers, whose average is 9.12%.

Portfolio Pulse from Benzinga Insights

July 26, 2024 | 8:45 pm

SBUX

Howard Schultz, former CEO of Starbucks, opposes a potential settlement between Starbucks and activist investor Elliott Investment Management. Schultz, who remains a significant shareholder, has publicly criticized the company's leadership and performance. Starbucks has faced a 20% decline in share price since the start of 2024 and has cut its financial guidance twice this year. The company is set to announce its fiscal third-quarter results soon.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 8:39 pm

ALRN

Aileron Therapeutics has entered into an equity distribution agreement, allowing the company to offer and sell shares of its common stock up to $50 million, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 8:38 pm

VTVT

vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program, including the ongoing CATT1 phase 3 trial in type 1 diabetes.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 8:37 pm

VTVT

vTv Therapeutics shares have resumed trading after a temporary halt. Investors should monitor the stock for potential volatility.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 8:35 pm